Pathophysiology

Asthma in the Workplace and Related Conditions: Third Edition

Volumn , Issue , 2006, Pages 109-140

  Maestrelli, Piero ^a   Fabbri, Leonardo M ^b   Mapp, Cristina E ^c  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^c UNIVERSITY OF FERRARA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 34250020915     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.3109/9780849374531-8     Document Type: Chapter

References (207)

1. Wiggs B, Moreno R, James A, Hogg J, Pare PD. A model of the mechanics of airway narrowing in asthma. In: Kaliner MA, Barnes PJ, Persson CGA, eds. Asthma: Its Pathology and Treatment. New York: Marcel Dekker, 1991:73-101.
2. Persson CGA. Microvascular-epithelial exudation of bulk plasma in airway defense, disease, and repair. In: Holgate ST, Busse WW, eds. Inflammatory Mechanisms in Asthma. New York, Basel, Hong Kong: Marcel Dekker, 1998 (Chapter 26).
3. Vandenplas O, Malo JL. Inhalation challenges with agents causing occupational asthma. Eur Respir J 1997; 10(11):2612-2629.
4. Stenton SC. Determinants of whether occupational agents cause early, late, or dual asthmatic responses. Occup Med 2000; 15:431-444.
5. Chan-Yeung M, Grzybowski S. Prognosis in occupational asthma (editorial). Thorax 1985; 40(4):241-243.
6. Allard C, Cartier A, Ghezzo H, Malo JL. Occupational asthma due to various agents. Absence of clinical and functional improvement at an interval of four or more years after cessation of exposure. Chest 1989; 96(5):1046-1049.
7. Cote J, Kennedy S, Chan-Yeung M. Outcome of patients with cedar asthma with continuous exposure. Am Rev Respir Dis 1990; 141(2):373-376.
8. Mapp CE, Corona PC, De Marzo N, Fabbri L. Persistent asthma due to isocyanates. A follow-up study of subjects with occupational asthma due to toluene diisocyanate (TDI). Am Rev Respir Dis 1988; 137(6):1326-1329.
9. Vedal S, Enarson DA, Chan H, Ochnio J, Tse KS, Chan-Yeung M. A longitudinal study of the occurrence of bronchial hyperresponsiveness in western red cedar workers. Am Rev Respir Dis 1988; 137(3):651-655.
10. Panhuysen CI, Vonk JM, Koeter GH, Schouten JP, van Altena R, Bleecker ER, Postma DS. Adult patients may outgrow their asthma: a 25-year follow-up study [published erratum appears in Am J Respir Crit Care Med 1997; 156(2 Pt 1):674]. Am J Respir Crit Care Med 1997; 155(4):1267-1272.
11. Redington AE, Howarth PH. Airway wall remodelling in asthma [editorial, see comments]. Thorax 1997; 52(4):310-312.
12. Redington AE, Sime PJ, Howarth PH, Holgate ST. Fibroblast and the extracellular matrix in asthma. In: Holgate ST, Busse WW, eds. Inflammatory Mechanisms in Asthma. New York, Basel, Hong Kong: Marcel Dekker, 1998: chapter 21.
13. Macklem PT. Mechanical factors determining maximum bronchoconstriction. Eur Respir J Suppl 1989; 6:516S-519S.
14. Ebina M, Yaegashi H, Chiba R, Takahashi T, Motomiya M, Tanemura M. Hyperreac-tive site in the airway tree of asthmatic patients revealed by thickening of bronchial muscles. A morphometric study. Am Rev Respir Dis 1990; 141(5 Pt 1):1327-1332.
15. Paggiaro PL, Paoletti P, Bacci E. Eosinophils in bronchoalveolar lavage (BAL) of patients with toluene diisocyanate (TDI) asthma after cessation of work. Chest 1990(98):536-542.
16. Saetta M, Maestrelli P, DiStefano A, et al. Effect of cessation of exposure to toluene diisocyanate (TDI) on bronchial mucosa of subjects with TDI-induced asthma. Am Rev Respir Dis 1992; 145(1):169-174.
17. Saetta M, Maestrelli P, Turato G, et al. Airway wall remodeling after cessation of exposure to isocyanates in sensitized asthmatic subjects. Am J Respir Crit Care Med 1995; 151(2 Pt 1):489-494.
18. Maghni K, Lemiere C, Ghezzo H, Yuquan W, Malo J-L. Airway inflammation after cessation of exposure to agents causing occupational asthma. Am J Respir Crit Care Med 2003; 169:367-372.
19. Chan-Yeung M. Occupational asthma. Environ Health Perspect 1995; 6:249-252.
20. Venables KM, Chan-Yeung M. Occupational asthma. Lancet 1997; 349(9063):1465-1469.
21. O’Byrne PM. Mechanisms of airway hyperresponsiveness. In: Holgate ST, Busse WW, eds. Inflammatory Mechanisms in Asthma. New York, Basel, Hong Kong: Marcel Dekker, 1998 (chapter 34).
22. Hargreave FE, Ramsdale EH, Pugsley SO. Occupational asthma without bronchial hyperresponsiveness. Am Rev Respir Dis 1984; 130(3):513-515.
23. Mapp CE, Dal Vecchio L, Boschetto P, De Marzo N, Fabbri LM. Toluene diisocya-nate-induced asthma without airway hyperresponsiveness. Eur J Respir Dis 1986; 68(2): 89-95.
24. Mapp CE, Di Giacomo GR, Omini C, Broseghini C, Fabbri LM. Late, but not early, asthmatic reactions induced by toluene-diisocyanate are associated with increased air-way responsiveness to methacholine. Eur J Respir Dis 1986; 69(4):276-284.
25. Cartier A, L’Archeveque J, Malo JL. Exposure to a sensitizing occupational agent can cause a long-lasting increase in bronchial responsiveness to histamine in the absence of significant changes in airway caliber. J Allergy Clin Immunol 1986; 78(6):1185-1189.
26. Thorpe JE, Steinberg D, Bernstein IL, Murlas CG. Bronchial reactivity increases soon after the immediate response in dual-responding asthmatic subjects. Chest 1987; 91(1): 21-25.
27. Steinberg DR, Bernstein DI, Bernstein IL, Murlas CG. Prednisone pretreatment leads to histaminic airway hyporeactivity soon after resolution of the immediate allergic response. Chest 1989; 95(2):314-319.
28. Durham SR, Graneek BJ, Hawkins R, Newman-Taylor AJ. The temporal relationship between increases in airway responsiveness to histamine and late asthmatic responses induced by occupational agents. J Allergy Clin Immunol 1987; 79(2):398-406.
29. Josephs LK, Gregg I, Mullee MA, Holgate ST. Nonspecific bronchial reactivity and its relationship to the clinical expression of asthma. A longitudinal study. Am Rev Respir Dis 1989; 140(2):350-357.
30. Postma DS, Kerstjens HA. Characteristics of airway hyperresponsiveness in asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 158(5 Pt 3): S187-S192.
31. Banks DE, Rando RJ, Barkman HW Jr. Persistence of toluene diisocyanate-induced asthma despite negligible workplace exposures. Chest 1990; 97(1):121-125.
32. Padoan M, Pozzato V, Simoni M, et al. Long-term follow-up of toluene diisocyanate-induced asthma. Eur Respir J 2003; 21:637-640.
33. Maestrelli P, DeMarzo N, Saetta M, Boscaro M, Fabbri LM, Mapp CE. Effects of inhaled beclomethasone on airway responsiveness in occupational asthma. Am Rev Respir Dis 1993; 148:407-412.
34. Malo JL, Cartier A, Cote J, et al. Influence of inhaled steroids on recovery from occup-tional asthma after cessation of exposure: an 18 month double-blind cross over study. Am Rev Respir Dis 1996; 153:953-960.
35. Lam S, LeRiche J, Phillips D, Chan-Yeung M. Cellular and protein changes in bron-chial lavage fluid after late asthmatic reaction in patients with red cedar asthma. J Allergy Clin Immunol 1987; 80(1):44-50.
36. Chan-Yeung M, Leriche J, Maclean L, Lam S. Comparison of cellular and protein changes in bronchial lavage fluid of symptomatic and asymptomatic patients with red cedar asthma on follow-up examination. Clin Allergy 1988; 18(4):359-365.
37. De Meer G, Heederik D, Postma DS. Bronchial responsiveness to adenosine 5'-monophosphate and methacholine differ in their relationship with airway allergy and baseline FEV1. Am J Respir Crit Care Med 2002; 165:317-318.
38. De Meer G, Heederik D, Postma DS. Bronchial responsiveness to adenosine 5'-monophosphate and methacholine as predictors for nasal symptoms due to newly introduced allergens. A follow-up study among laboratory animal workers and bakery apprentices. Clin Exp Allergy 2003; 33:789-794.
39. Malo JL. Irritant-induced asthma and reactive airways dysfunction syndrome. Can Respir J 1998; 5:66-67.
40. Tarlo SM. Workplace irritant exposures: do they produce true occupational asthma? Ann Allergy Asthma Immunol 2003; 90(5 S2):19-23.
41. Gautrin D, Boulet LP, Boutet M, et al. Is reactive airways dysfunction syndrome a variant of occupational asthma? J Allergy Clin Immunol 1994; 93:12-22.
42. Lemiere C, Malo JL, Boutet M. Reactive airways dysfunction syndrome due to chlorine: sequential bronchial biopsies and functional assessment. Eur Respir J 1997; 10: 241-244.
43. Matzinger P. The danger model: a renewed sense of self. Science 2002; 296:301-305.
44. Humbert M, Durham SR, Ying S, et al. IL-4 and IL-5 mRNA and protein in bronchial biopsies from patients with atopic and nonatopic asthma: evidence against ‘‘intrinsic’’ asthma being a distinct immunopathologic entity. Am J Respir Crit Care Med 1996; 154(5):1497-1504.
45. Humbert M, Ying S, Corrigan C, et al. Bronchial mucosal expression of the genes encoding chemokines RANTES and MCP-3 in symptomatic atopic and nonatopic asth-matics: relationship to the eosinophil-active cytokines interleukin (IL)-5, granulocyte macrophage-colony-stimulating factor, and IL-3. Am J Respir Cell Mol Biol 1997; 16(1):1-8.
46. Ying S, Humbert M, Barkans J, et al. Expression of IL-4 and IL-5 mRNA and protein product by CD4+ and CD8+ T cells, eosinophils, and mast cells in bronchial biopsies obtained from atopic and nonatopic (intrinsic) asthmatics. J Immunol 1997; 158(7): 3539-3544.
47. Humbert M, Durham SR, Kimmitt P, et al. Elevated expression of messenger ribonu-cleic acid encoding IL-13 in the bronchial mucosa of atopic and nonatopic subjects with asthma. J Allergy Clin Immunol 1997; 99(5):657-665.
48. Humbert M, Corrigan CJ, Kimmitt P, Till SJ, Kay AB, Durham SR. Relationship between IL-4 and IL-5 mRNA expression and disease severity in atopic asthma. Am J Respir Crit Care Med 1997; 156(3 Pt 1):704-708.
49. Bentley AM, Menz G, Storz C, et al. Identification of T lymphocytes, macrophages, and activated eosinophils in the bronchial mucosa in intrinsic asthma. Relationship to symptoms and bronchial responsiveness. Am Rev Respir Dis 1992; 146(2):500-506.
50. Humbert M, Grant JA, Taborda-Barata L, et al. High-affinity IgE receptor (Fcepsi-lonRI)-bearing cells in bronchial biopsies from atopic and nonatopic asthma. Am J Respir Crit Care Med 1996; 153(6 Pt 1):1931-1937.
51. Kotsimbos AT, Humbert M, Minshall E, et al. Upregulation of alpha GM-CSF-receptor in nonatopic asthma but not in atopic asthma. J Allergy Clin Immunol 1997; 99(5):666-672.
52. Halapi E, Hakonarson H. Recent development in genomic and proteomic research for asthma. Curr Opin Pulm Med 2004; 10:22-30.
53. Bel EH. Clinical phenotypes of asthma. Curr Opin Pulm Med 2004; 10:44-50.
54. Mapp CE, Beghe B, Balboni A, et al. Association between HLA genes and susceptibility to toluene diisocyanate induced asthma. Clin Exp Allergy 2000; 5:651-656.
55. Jones MG, Nielsen J, Welch J, et al. Association of HLA-DQ5 and HLA-DR1 with sensitisation to organic acid anhydrides. Clin Exp Allergy 2004; 34:812-816.
56. Jeal H, Draper A, Jones M, et al. HLA associations with occupational sensitisation to rat lipocalin allergens: a model for other animal allergies? J Allergy Clin Immunol 2003; 111:795-799.
57. Arnaiz NO, Kaufman JD, Daroowalla FM, Quigley S, Farin F, Checkoway H. Genetic factors in aluminium smelter workers. Arch Environ Health 2003; 58:197-200.
58. Beghe B, Padoan M, Moss CT, et al. Lack of association of HLA class I genes and TNF alpha-308 polymorphism in toluene diisocyanate-induced asthma. Allergy 2004; 59:61-64.
59. Piirila P, Wikman H, Luukkonen R, et al. Glutathione S-transferase genotypes in allergic responses to diisocyanate exposure. Pharmacogenetics 2001; 11:437-441.
60. Mapp CE, Fryer AA, De Marzo N, et al. Glutathione S-transferase GSTP1 is a suscept-ibility gene for occupational asthma induced by isocyanates. J Allergy Clin Immunol 2002; 109:867-872.
61. Fryer AA, Bianco A, Hepple M, Jones PW, Strange RC, Spiteri MA. Polymorphism at the glutathione S-transferase GSTP1 locus. A new marker for bronchial hyperresponsiveness and asthma. Am J Respir Crit Care Med 2000; 161:1437-1442.
62. Aynacioglu AS, Nacak M, Filiz A, Ekinci E. Roots Protective role of glutathione S-transferase P1 (GSTP1) Val105Val genotype in patients with bronchial asthma. Br J Clin Pharmacol 2004; 57:213-217.
63. Romieu I, Sienra-Monge JJ, Ramirez-Aguilar M, et al. Genetic polymorphism of GSTM1 and antioxidant supplementation influence lung function in relation to ozone exposure in asthmatic children in Mexico City. Thorax 2004; 59:8-10.
64. Gilliland FD, Li YF, Saxon A, Diaz-Sanchez D. Effect of glutathione-S-transferase M1 and P1 genotypes on xenobiotic enhancement of allergic responses: randomised, placebo-controlled crossover study. Lancet 2004; 363:119-125.
65. Wikman H, Piirila P, Rosenberg C, et al. N-acetyltransferase genotypes as modifiers of diisocyanate exposure-associated asthma risk. Pharmacogenetics 2002; 12:227-233.
66. Barnes KC, Marsh DG. The genetics and complexity of allergy and asthma. Immunol Today 1998; 19(7):325-332.
67. Young RP, Barker RD, Pile KD, Cookson OCM, Newman-Taylor AJ. The association of HLA-DR3 with specific IgE to inhaled acid anhydrides. Am J Respir Crit Care Med 1995; 151(1):219-221.
68. Newman Taylor AJ, Cullinan P, Lympany PA, Harris JM, Dowdeswell RJ, du Bois RM. Interaction of HLA phenotype and exposure intensity in sensitization to complex plati-num salts. Am J Respir Crit Care Med 1999; 160(2):435-438.
69. Maestrelli P, Di Stefano A, Occari P, et al. Cytokines in the airway mucosa of subjects with asthma induced by toluene diisocyanate. Am J Respir Crit Care Med 1995; 151(3 Pt 1): 607-612.
70. Durham SR. Mechanisms of mucosal inflammation in the nose and lungs. Clin Exp Allergy 1998; 2:11-16.
71. Costa JJ, Galli SJ, Church MK. Mast cell cytokines in allergic inflammation. In: Holgate ST, Busse WW, eds. Inflammatory Mechanisms in Asthma. New York, Base, Hong Kong: Marcel Dekker, 1998: chapter 6.
72. Novey HS, Bernstein IL, Mihalas LS, Terr AI, Yunginger JW. Guidelines for the clinical evaluation of occupational asthma due to high molecular weight (HMW) aller-gens. Report of the Subcommittee on the Clinical Evaluation of Occupational Asthma due to HMW llergens. J Allergy Clin Immunol 1989; 84(5 Pt 2):829-833.
73. Maccia CA, Bernstein IL, Emmett EA, Brooks SM. In vitro demonstration of specific IgE in phthalic anhydride hypersensitivity. Am Rev Respir Dis 1976; 113(5):701-704.
74. Biagini RE, Bernstein IL, Gallagher JS, Moorman WJ, Brooks S, Gann PH. The diver-sity of reaginic immune responses to platinum and palladium metallic salts. J Allergy Clin Immunol 1985; 76(6):794-802.
75. Cartier A, Grammer L, Malo JL, et al. Specific serum antibodies against isocyanates: association with occupational asthma. J Allergy Clin Immunol 1989; 84(4 Pt 1):507-514.
76. Tse KS, Chan H, Chan-Yeung M. Specific IgE antibodies in workers with occupational asthma due to western red cedar. Clin Allergy 1982; 12(3):249-258.
77. Cartier A, Malo JL, Forest F, et al. Occupational asthma in snow crab-processing workers. J Allergy Clin Immunol 1984; 74(3 Pt 1):261-269.
78. Mitchell CA, Gandevia B. Respiratory symptoms and skin reactivity in workers exposed to proteolytic enzymes in the detergent industry. Am Rev Respir Dis 1971; 104(1):1-12.
79. Karr RM. Bronchoprovocation studies in coffee worker’s asthma. J Allergy Clin Immunol 1979; 64(6 pt 2):650-654.
80. Davison AG, Britton MG, Forrester JA, Davies RJ, Hughes DT. Asthma in merchant seamen and laboratory workers caused by allergy to castor beans: analysis of allergens. Clin Allergy 1983; 13(6):553-561.
81. Merget R, Stollfuss J, Wiewrodt R, et al. Diagnostic tests in enzyme allergy. J Allergy Clin Immunol 1993; 92(2):264-277.
82. Bernstein DI, Smith AB, Moller DR, et al. Clinical and immunologic studies among egg-processing workers with occupational asthma. J Allergy Clin Immunol 1987; 80(6): 791-797.
83. Tiikkainen U, Klockars M. Clinical significance of IgG subclass antibodies to wheat flour antigens in bakers. Allergy 1990; 45(7):497-504.
84. Popp W, Zwick H, Rauscher H. Short-term sensitizing antibodies in bakers’ asthma. Int Arch Allergy Appl Immunol 1988; 86(2):215-219.
85. Tee RD, Cullinan P, Welch J, Burge PS, Newman-Taylor AJ. Specific IgE to isocya-nates: a useful diagnostic role in occupational asthma. J Allergy Clin Immunol 1998; 101(5):709-715.
86. Nielsen J, Welinder H, Skerfving S. Allergic airway disease caused by methyl tetrahy-drophthalic anhydride in epoxy resin. Scand J Work Environ Health 1989; 15(2): 154-155.
87. Bernstein DI, Gallagher JS, D’Souza L, Bernstein IL. Heterogeneity of specific-IgE responses in workers sensitized to acid anhydride compounds. J Allergy Clin Immunol 1984; 74(6):794-801.
88. Zeiss CR, Wolkonsky P, Pruzansky JJ, Patterson R. Clinical and immunologic evalua-tion of trimellitic anhydride workers in multiple industrial settings. J Allergy Clin Immunol 1982; 70(1):15-18.
89. Ahmad D, Morgan WK, Patterson R, Williams T, Zeiss CR. Pulmonary haemorrhage and haemolytic anaemia due to trimellitic anhydride. Lancet 1979; 2(8138):328-330.
90. Patterson R, Addington W, Banner AS, et al. Antihapten antibodies in workers exposed to trimellitic anhydride fumes: a potential immunopathogenetic mechanism for the trimellitic anhydride pulmonary disease—anemia syndrome. Am Rev Respir Dis 1979; 120(6):1259-1267.
91. Turner ES, Pruzansky JJ, Patterson R, Zeiss CR, Roberts M. Detection of antibodies in human serum using trimellityl-erythrocytes: direct and indirect haemagglutination and haemolysis. Clin Exp Immunol 1980; 39(2):470-476.
92. Venables KM, Topping MD, Nunn AJ, Howe W, Newman Taylor AJ. Immunologic and functional consequences of chemical (tetrachlorophthalic anhydride)-induced asthma after four years of avoidance of exposure. J Allergy Clin Immunol 1987; 80(2): 212-218.
93. Zhang XD, Lotvall J, Skerfving S, Welinder H. Antibody specificity to the chemical structures of organic acid anhydrides studied by in-vitro and in-vivo methods. Toxicol-ogy 1997; 118(2-3):223-232.
94. Zhang XD, Welinder H, Jonsson BA, Skerfving S. Antibody responses of rats after immunization with organic acid anhydrides as a model of predictive testing. Scand J Work Environ Health 1998; 24:220-227.
95. Cleare MJ, Hughes EG, Jacoby B, Pepys J. Immediate (type I) allergic responses to platinum compounds. Clin Allergy 1976; 6(2):183-195.
96. Venables KM, Dally MB, Nunn AJ, et al. Smoking and occupational allergy in workers in a platinum refinery. BMJ 1989; 299(6705):939-942.
97. Pepys J, Parish WE, Cromwell O, Hughes EG. Passive transfer in man and the monkey of Type I allergy due to heat labile and heat stable antibody to complex salts of plati-num. Clin Allergy 1979; 9(2):99-108.
98. Baker DB, Gann PH, Brooks SM, Gallagher J, Bernstein IL. Cross-sectional study of platinum salts sensitization among precious metals refinery workers. Am J Ind Med 1990; 18(6):653-664.
99. Biagini RE, Klincewicz SL, Henningsen GM, et al. Antibodies to morphine in workers exposed to opiates at a narcotics manufacturing facility and evidence for similar antibodies in heroin abusers. Life Sci 1990; 47(10):897-908.
100. Ban M, Hettich D. Relationship between IgE positive cell numbers and serum total IgE levels in mice treated with trimellitic anhydride and dinitrochlorobenzene. Toxicol Lett 2001; 118:129-137.
101. Farraj AK, Harkema JR, Kaminski NE. Allergic rhinitis induced by intranasal sensiti-zation and challenge with trimellitic anhydride but not with dinitrochlorobenzene or oxazolone in A/J mice. Toxicol Sci 2004; 79:315-325.
102. Dearman RJ, Warbrick EV, Skinner R, Kimber I. Cytokine fingerprinting of chemical allergens: species comparisons and statistical analyses. Food Chem Toxicol 2002; 40:1881-1892.
103. Hayashi M, Higashi K, Kato H, Kaneko H. Assessment of preferential Th1 or Th2 induc-tion by low-molecular-weight compounds using a reverse transcription-polymerase chain reaction method: comparison of two mouse strains, C57BL/6 and BALB/c. Toxicol Appl Pharmacol 2001; 177:38-45.
104. Herrick CA, Das J, Xu L, Wisnewski AV, Redlich CA, Bottomly K. Differential roles for CD4 and CD8T cells after diisocyanate sensitization: genetic control of TH2-induced lung inflammation. J Allergy Clin Immunol 2003; 111:1087-1094.
105. Bentley AM, Maestrelli P, Saetta M, et al. Activated T-lymphocytes and eosinophils in the bronchial mucosa in isocyanate-induced asthma. J Allergy Clin Immunol 1992; 89:821-829.
106. Maestrelli P, Occari P, Turato G, et al. Expression of interleukin (IL)-4 and IL-5 proteins in asthma induced by toluene diisocyanate (TDI). Clin Exp Allergy 1997; 27: 1292-1298.
107. Grammer L, Shaughnessy M, Kenamore B. Utility of antibody in identifying indivi-duals who have or will develop anhydride-induced respiratory disease. Chest 1998; 114:1199-1202.
108. Vandenplas O, Malo JL, Saetta M, Mapp CE, Fabbri LM. Occupational asthma and extrinsic alveolitis due to isocyanates: current status and perspectives. Br J Ind Med 1993; 50:213-228.
109. Tarlo SM. Diisocyanate sensitization and antibody production. J Allergy Clin Immunol 1999; 103:739-741.
110. Walker C, Bode E, Boer L, Hansel TT, Blaser K, Virchow JC Jr. Allergic and nonaller-gic asthmatics have distinct patterns of T-cell activation and cytokine production in peripheral blood and bronchoalveolar lavage. Am Rev Respir Dis 1992; 146(1):109-115.
111. Del Prete GF, De Carli M, D’Elios MM, Maestrelli P, Ricci M, Fabbri L, Romagnani S. Allergen exposure induces the activation of allergen-specific Th2 cells in the airway mucosa of patients with allergic respiratory disorders. Eur J Immunol 1993; 23(7): 1445-1449.
112. Maestrelli P, Del Prete GF, De Carli M, et al. CD8 T-cell clones producing interleukin-5 and interferon-gamma in bronchial mucosa of patients with asthma induced by toluene diisocyanate. Scand J Work Environ Health 1994; 20(5):376-381.
113. Wisnewski AV, Cain H, Magoski N, Wang H, Holm CT, Redlich CA. Human gamma/ delta T-cell lines derived from airway biopsies. Am J Respir Cell Mol Biol 2001; 24: 332-338.
114. Wisnewski AV, Herrick CA, Liu Q, Chen L, Bottomly K, Redlich CA. Human gamma/ delta T-cell proliferation and IFN-gamma production induced by hexamethylene diiso-cyanate. J Allergy Clin Immunol 2003; 112:538-546.
115. Frew A, Chang JH, Chan H, et al. T-lymphocyte responses to plicatic acid-human serum albumin conjugate in occupational asthma caused by western red cedar. J Allergy Clin Immunol 1998; 101(6 Pt 1):841-847.
116. Herrick CA, Xu L, Wisnewski AV, Das J, Redlich CA, Bottomly K. A novel mouse model of diisocyanate-induced asthma showing allergic-type inflammation in the lung after inhaled antigen challenge. J Allergy Clin Immunol 2002; 109:873-878.
117. Matheson JM, Lemus R, Lange RW, Karol MH, Luster MI. Role of tumor necrosis factor in toluene diisocyanate asthma. Am J Respir Cell Mol Biol 2002; 27:396-405.
118. Herrick CA, Das J, Xu L, Wisnewski AV, Redlich CA, Bottomly K. Differential roles for CD4 and CD8 T cells after diisocyanate sensitization: Genetic control of TH2-induced lung inflammation. J Allergy Clin Immunol 2003; 111:1087-1094.
119. Lummus ZL, Alam R, Bernstein JA, Bernstein DI. Diisocyanate antigen-enhanced production of monocyte chemoattractant protein-1, IL-8, and tumor necrosis factor-alpha by peripheral mononuclear cells of workers with occupational asthma. J Allergy Clin Immunol 1998; 102(2):265-274.
120. Gallagher JS, Tse CS, Brooks SM, Bernstein IL. Diverse profiles of immunoreactivity in toluene diisocyanate (TDI) asthma. J Occup Med 1981; 23(9):610-616.
121. Shirakawa T, Morimoto K. Brief reversible bronchospasm resulting from bichromate exposure. Arch Environ Health 1996; 51(3):221-226.
122. Holgate ST. The cellular and mediator basis of asthma in relation to natural history. Lancet 1997; 350(2):S115-119.
123. Boushey HA, Fahy JV. Basic mechanisms of asthma. Environ Health Perspect 1995; 6:229-233.
124. Holgate ST, Bradding P, Sampson AP. Leukotriene antagonists and synthesis inhibi-tors: new directions in asthma therapy. J Allergy Clin Immunol 1996; 98(1):1-13.
125. Li JT. Mechanisms of asthma. Curr Opin Pulm Med 1997; 3(1):10-16.
126. Barnes PJ. Airway neuropeptides and their role in asthma. In: Holgate ST, Busse WW, eds. Inflammatory Mechanisms in Asthma. New York, Basel, Hong Kong: Marcel Dekker, 1998: chapter 24.
127. Fabbri LM, Danieli D, Crescioli S, Bevilacqua P, Meli S, Saetta M, Mapp CE. Fatal asthma in a subject sensitized to toluene diisocyanate. Am Rev Respir Dis 1988; 137(6):1494-1498.
128. Saetta M, Di Stefano A, Rosina C, Thiene G, Fabbri LM. Quantitative structural analysis of peripheral airways and arteries in sudden fatal asthma. Am Rev Respir Dis 1991; 143(1):138-143.
129. Saetta M, Di Stefano A, Maestrelli P, et al. Airway mucosal inflammation in occupational asthma induced by toluene diisocyanate. Am Rev Respir Dis 1992; 145(1): 160-168.
130. Montefort S, Roberts JA, Beasley R, Holgate ST, Roche WR. The site of disruption of the bronchial epithelium in asthmatic and non- asthmatic subjects. Thorax 1992; 47(7):499-503.
131. Montefort S, Djukanovic R, Holgate ST, Roche WR. Ciliated cell damage in the bronchial epithelium of asthmatics and non-asthmatics. Clin Exp Allergy 1993; 23(3): 185-189.
132. Roche WR, Beasley R, Williams JH, Holgate ST. Subepithelial fibrosis in the bronchi of asthmatics. Lancet 1989; 1(8637):520-524.
133. Brewster CE, Howarth PH, Djukanovic R, Wilson J, Holgate ST, Roche WR. Myofibroblasts and subepithelial fibrosis in bronchial asthma. Am J Respir Cell Mol Biol 1990; 3(5):507-511.
134. Frew AJ, Chan H, Lam S, Chan-Yeung M. Bronchial inflammation in occupational asthma due to western red cedar. Am J Respir Crit Care Med 1995; 151(2 Pt 1):340-344.
135. Gautrin D, Boulet LP, Boutet M, et al. Is reactive airways dysfunction syndrome a variant of occupational asthma?. J Allergy Clin Immunol 1994; 93(1 Pt 1):12-22.
136. Barbato A, Turato G, Baraldo S, et al. Airway inflammation in childhood asthma. Am J Respir Crit Care Med 2003; 168:798-803.
137. Gizycki MJ, Adelroth E, Rogers AV, O’Byrne PM, Jeffery PK. Myofibroblast involve-ment in the allergen-induced late response in mild atopic asthma. Am J Respir Cell Mol Biol 1997; 16(6):664-673.
138. Trigg CJ, Manolitsas ND, Wang J, et al. Placebo-controlled immunopathologic study of four months of inhaled corticosteroids in asthma. Am J Respir Crit Care Med 1994; 150(1):17-22.
139. Olivieri D, Chetta A, Del Donno M, et al. Effect of short-term treatment with low-dose inhaled fluticasone propionate on airway inflammation and remodeling in mild asthma: a placebo-controlled study. Am J Respir Crit Care Med 1997; 155(6):1864-1871.
140. Crimi E, Spanevello A, Neri M, et al. Dissociation between airway inflammation and airway hyperresponsiveness in allergic asthma [see comments]. Am J Respir Crit Care Med 1998; 157(1):4-9.
141. Chetta A, Foresi A, Del Donno M, et al. Bronchial responsiveness to distilled water and methacholine and its relationship to inflammation and remodeling of the airways in asthma. Am J Respir Crit Care Med 1996; 153(3):910-917.
142. Peters SP, Shaver JR, Zangrilli JG, Fish JE. Airways responses to antigen in asthmatic and nonasthmatic subjects. In: Holgate ST, Busse WW, eds. Inflammatory Mechanisms in Asthma. New York, Basel, Hong Kong: Marcel Dekker, 1998 (chapter 7).
143. Sheth KK, Lemanske RF. The early and late asthmatic reaction to allergen. In: Holgate ST, Busse WW, eds. Inflammatory Mechanisms in Asthma. New York, Basel, Hong Kong: Marcel Dekker, 1998: chapter 34.
144. Fabbri LM, Boschetto P, Zocca E, et al. Bronchoalveolar neutrophilia during late asthmatic reactions induced by toluene diisocyanate. Am Rev Respir Dis 1987; 136(1): 36-42.
145. Chan-Yeung M, Lam S. Evidence for mucosal inflammation in occupational asthma. Clin Exp Allergy 1990; 20(1):1-5.
146. Zocca E, Fabbri LM, Boschetto P, et al. Leukotriene B4 and late asthmatic reactions induced by toluene diisocyanate. J Appl Physiol 1990; 68(4):1576-1580.
147. White SR, Leff AR. Epithelium as a target. In: Holgate ST, Busse WW, eds. Inflammatory Mechanism in Asthma. New York, Basel, Hong Kong: Marcel Dekker, 1998: chapter 23.
148. Chan-Yeung M, Chan H, Tse KS, Salari H, Lam S. Histamine and leukotrienes release in bronchoalveolar fluid during plicatic acid-induced bronchoconstriction. J Allergy Clin Immunol 1989; 84(5 Pt 1):762-768.
149. Manning PJ, Rokach J, Malo JL, et al. Urinary leukotriene E4 levels during early and late asthmatic responses. J Allergy Clin Immunol 1990; 86(2):211-220.
150. Larche M, Robinson DS, Kay AB. The role of T lymphocytes in the pathogenesis of asthma. J Allergy Clin Immunol 2003; 111:450-463.
151. Djukanovic R, Sterk PJ, Fahy JV, Hargreave FE, eds. Standardized methodology of sputum induction and processing. Eur Respir J 2002; 20(suppl 37):1S-55S.
152. Maestrelli P, Saetta M, Di Stefano A, Calcagni PG, Turato G, Ruggieri MP, Roggeri A, Mapp CE, Fabbri LM. Comparison of leukocyte counts in sputum, bronchial biopsies and bronchoalveolar lavage. Am J Respir Crit Care Med 1995; 152:1926-1931.
153. Pizzichini E, Pizzichini MM, Efthimiadis A, Evans S, Morris MM, Squillace D, Gleich GJ, Dolovich J, Hargreave FE. Indices of airway inflammation in induced sputum: reprodu-cibility and validity of cell and fluid-phase measurements. Am J Respir Crit Care Med 1996; 154:308-307.
154. Pavord ID, Pizzichini MM, Pizzichini E, Hargreave FE. The use of induced sputum to investigate airway inflammation. Thorax 1997; 52:498-501.
155. Kips JC, Kharitonov SA, Barnes PJ. Noninvasive assessment of airway inflammation in asthma. Eur Respir Mon 2003; 23:164-179.
156. Maestrelli P, Calcagni P, Saetta M, et al. Sputum eosinophilia after asthmatic responses induced by isocyanates in sensitized subjects. Clin Exp Allergy 1994; 24:29-34.
157. Lemiere C, Pizzichini MM, Balkissoon R, et al. Diagnosing occupational asthma: use of induced sputum. Eur Respir J 1999; 13:482-488.
158. Lemiere C, Romeo P, Chaboillez S, Tremblay C, Malo JL. Airway inflammation and functional changes after exposure to different concentrations of isocyanates. J Allergy Clin Immunol 2002; 110:641-646.
159. Obata H, Dittrick M, Chan H, Chan-Yeung M. Sputum eosinophils and exhaled nitric oxide during late asthmatic reaction in patients with western red cedar. Eur Respir J 1999; 13:489-495.
160. Lemiere C, Chaboillez S, Malo JL, Cartier A. Changes in sputum cell counts after exposure to occupational agents: what do they mean? J Allergy Clin Immunol 2001; 107: 1063-1068.
161. Panzer SE, Dodge AM, Kelly EAB, Jarjour N. Circadian variation of sputum inflammatory cells in mild asthma. J Allergy Clin Immunol 2003; 111:308-312.
162. Sastre J, Vandenplas O, Park H-S. Pathogenesis of occupational asthma. Eur Respir J 2003; 22:364-373.
163. Lemiere C, Chaboilliez S, Trudeau C, Taha R, Maghni K, Martin JG, Hamid Q. Characterization of airway inflammation after repeated exposures to occupational agents. J Allergy Clin Immunol 2000; 106:1163-1170.
164. Chan-Yeung M, Obata H, Dittrick M, Chan H, Abboud R. Airway inflammation, exhaled nitric oxide, and severity of asthma in patients with western red cedar asthma. Am J Respir Crit Care Med 1999; 159:1434-1438.
165. Quirce S, Fernandez-Nieto M, de Migule J, Sastre J. Chronic cough due to latex-induced eosinophilic bronchitis. J Allergy Clin Immunol 2001; 108:143.
166. Lemiere C, Efthimiadis A, Hargreave FE. Occupational eosinophilic bronchitis without asthma: an unknown occupational airway disease. J Allergy Clin Immunol 1997; 100: 852-853.
167. Bates CA, Silkoff PE. Exhaled nitric oxide in asthma: from bench to bedside. J Allergy Clin Immunol 2003; 111:256-262.
168. Alving K, Weitzberg E, Lundberg J. Increased amount of nitric oxide in exhaled air of asthmatics. Eur Respir J 1993; 6:1368-1370.
169. Kharitonov S, O’Connor B, Evans D, Barnes P. Allergen-induced late asthmatic reac-tions are associated with elevation of exhaled nitric oxide. Am J Respir Crit Care Med 1995; 151:1894-1899.
170. Adisesh LA, Kharitonov SA, Yates DH, Snashell DC, Newman-Taylor AJ, Barnes PJ. Exhaled and nasal nitric oxide is increased in laboratory animal allergy. Clin Exp Allergy 1998; 28:876-880.
171. Olin AC, Ljungkvist G, Bake B, Hagberg S, Henriksson L, Toren K. Exhaled nitric oxide among pulpmill workers reporting gassing incidents involving ozone and chlorine dioxide. Eur Respir J 1999; 14:828-831.
172. Piipari R, Piirila P, Keskinen H, Tuppurainen M, Sovijarvi A, Nordman H. Exhaled nitric oxide in specific challenge tests to assess occupational asthma. Eur Respir J 2002; 20:1532-1537.
173. Gibson PG, Fujimura M, Niimi A. Eosinophilic bronchitis: clinical manifestations and implications for treatment. Thorax 2002; 57:178-182.
174. Quirce S. Eosinophilic bronchitis in the workplace. Curr Opin Allergy Clin Immunol 2004; 4:87-91.
175. Vandenplas O, Malo JL. Definitions and type of work-related asthma: a nosological approach. Eur Respir J 2003; 21:706-712.
176. Brightling CE, Woltmann G, Wardlaw AJ, Pavord ID. Development of irreversible airflow obstruction in a patient with eosinophilic bronchitis without asthma. Eur Respir J 1999; 14:1228-1230.
177. Hancox RJ, Leigh R, Kelly MM, Hargreave FE. Eosinophilic bronchitis. Lancet 2001; 358:1104.
178. Tanaka H, Saikai T, Sugawara H, Takeya I, Tsunematsu K, Matsuura A, Abe S. Work-place-related chronic cough on a mushroom farm. Chest 2002; 122:1080-1085.
179. Kobayashi O. A case of eosinophilic bronchitis due to epoxy resin system hardener, methl endo methylene tetrahydro phtalic anhydride. Arerugi 1994; 43:660-662.
180. Ogawa H, Fujimura M, Heki U, Kitagawa M, Matsuda T. Eosinophilic bronchitis presenting with only severe dry cough due to bucillamine. Respiratory Med 1995; 89: 219-221.
181. Brightling CE, Bradding P, Symon FA, Holgate ST, Wardlaw AJ, Pavord ID. Mast-cell infiltration of airway smooth muscle in asthma. N Eng J Med 2002; 346:1699-1705.
182. Brightling CE, Symon FA, Birring SS, Bradding P, Wardlaw AJ, Pavord ID. Compar-ison of airway immunopathology of eosinophilic bronchitis and asthma. Thorax 2003; 58:528-532.
183. Brightling CE, Ward R, Woltmann G, Bradding P, Sheller JR, Dworski R, Pavord ID. Induced sputum inflammatory mediator concentrations in eosinophilic bronchitis and asthma. Am J Respir Crit Care Med 2000; 162:878-882.
184. Birring SS, Parker D, Brightling CE, Bradding P, Wardlaw AJ, Pavord ID. Induced sputum inflammatory mediator concentrations in chronic cough. Am J Respir Crit Care Med. 2004; 169:15-19.
185. Gibson PG, Zlatic K, Scott J, Sewell W, Woolley K, Saltos N. Chronic cough resembles asthma with IL-5 and granulocyte-macrophage colony-stimulating factor gene expres-sion in bronchoalveolar cells. J Allergy Clin Immunol 1998; 101:320-326.
186. Brightling CE, Symon FA, Birring SS, Bradding P, Wardlaw AJ, Pavord ID. TH2 cytokine expression in bronchoalveolar lavage fluid T lymphocytes and bronchial submucosa is a feature of asthma and eosinophilic bronchitis. J Allergy Clin Immunol 2002; 110:899-905.
187. Tillie-Leblond I, Gosset P, Tonnel A-B. Inflammatory events in severe acute asthma. Allergy 2005; 60:23-29.
188. Fabbri LM, Boschetto P, Caramori G, Maestrelli P. Neutrophils and asthma. In: Holgate ST, Busse WW, eds. Inflammatory Mechanisms in Asthma. New York, Basel, Hong Kong: Marcel Dekker, 1998 (chapter 15).
189. Di Franco A, Vagaggini B, Bacci E, et al. Leukocyte counts in hypertonic saline-induced sputum in subjects with occupational asthma. Respir Med 1998; 92:550-557.
190. Anees W, Huggins V, Pavord ID, Robertson AS, Burge PS. Occupational asthma due to low molecular weight agents: eosinophilic and non-eosinophilic variants. Thorax 2002; 57:231-236.
191. Park H, Jung K, Kim H, Nahm D, Kang K. Neutrophil activation following TDI bronchial challenges to airway secretion from subjects with TDI-induced asthma. Clin Exp Allergy 1999; 29:1395-1401.
192. Jung KS, Park HS. Evidence for neutrophil activation in occupational asthma. Respirology 1999; 4:303-306.
193. Jatakanon A, Uasuf C, Maziak W, Lim S, Chung KF, Barnes PJ. Neutrophilic inflammation in severe persistent asthma. Am J Respir Crit Care Med 1999; 160:1532-1539.
194. Park HS, Hwang SC, Nahm DH, Yim HE. Immunohistochemical characterization of cellular infiltrate in airway mucosa of toluene diisocyanate-induced asthma. J Korean Med Sci 1998; 13:12-16.
195. Saite J, Banks DE, Lopez M, Barkman HW, Salvaggio JE. Neutrophil chemotactic activity in toluene diisocyanate (TDI)-induced asthma. J Allergy Clin Immunol 1990; 85: 567-572.
196. Park HS, Jung KS, Hwang SC, Nahm DH, Yim HE. Neutrophil infiltration and release of IL-8 in airway mucosa from subjects with grain dust-induced occupational asthma. Clin Exp Allergy 1998; 28:724-730.
197. Barnes PJ, Baraniuk JN, Belvisi MG. Neuropeptides in the respiratory tract. Part II. Am Rev Respir Dis 1991; 144(6):1391-1399.
198. Nadel JA. Neutral endopeptidase modulates neurogenic inflammation. Eur Respir J 1991; 4(6):745-754.
199. Heaney LG, Cross LJ, McGarvey LP, Buchanan KD, Ennis M, Shaw C. Neurokinin A is the predominant tachykinin in human bronchoalveolar lavage fluid in normal and asthmatic subjects. Thorax 1998; 53(5):357-362.
200. Barnes PJ. NO or no NO in asthma? Thorax 1996; 51(2):218-220.
201. Ollerenshaw SL, Jarvis D, Woolcock AJ, Sullivan CE, Scheibner T. Absence of immu-noreactive vasoactive intestinal polypeptide in tissue from the lung of patients with asthma. N Engl J Med 1991(320):1244-1248.
202. Ollerenshaw SL, Jarvis D, Sullivan CE, Woolcock AJ. Substance P immunoreactive nerves in airways from asthmatics and nonasthmatics. Eur Respir J 1991; 4(6):673-682.
203. Lilly CM, Bai TR, Shore SA, Hall AE, Drazen JM. Neuropeptide content of lungs from asthmatic and nonasthmatic patients. Am J Respir Crit Care Med 1995; 151(2 Pt 1): 548-553.
204. Howarth PH, Springall DR, Redington AE, Djukanovic R, Holgate ST, Polak JM. Neuropeptide-containing nerves in endobronchial biopsies from asthmatic and nonasth-matic subjects. Am J Respir Cell Mol Biol 1995; 13(3):288-696.
205. Mapp CE, Lucchini RE, Miotto D, et al. Immunization and challenge with toluene diisocyanate decrease tachykinin and calcitonin gene-related peptide immunoreactivity in guinea pig central airways. Am J Respir Crit Care Med 1998; 158(1):263-269.
206. Sheppard D, Thompson JE, Scypinski L, Dusser D, Nadel JA, Borson DB. Toluene diisocyanate increases airway responsiveness to substance P and decreases airway neutral endopeptidase. J Clin Invest 1988; 81(4):1111-1115.
207. O’Byrne PM. Leukotrienes in the pathogenesis of asthma. Chest 1997; 111(suppl 2): 27S-34S.